[go: up one dir, main page]

WO1996041634A3 - Utilisation d'un inhibiteur de transcriptase inverse non-nucleosidique en association avec des inhibiteurs de nucleosides pour le traitement d'infections a vih - Google Patents

Utilisation d'un inhibiteur de transcriptase inverse non-nucleosidique en association avec des inhibiteurs de nucleosides pour le traitement d'infections a vih Download PDF

Info

Publication number
WO1996041634A3
WO1996041634A3 PCT/EP1996/002540 EP9602540W WO9641634A3 WO 1996041634 A3 WO1996041634 A3 WO 1996041634A3 EP 9602540 W EP9602540 W EP 9602540W WO 9641634 A3 WO9641634 A3 WO 9641634A3
Authority
WO
WIPO (PCT)
Prior art keywords
association
treatment
nucleoside
hiv infection
reverse transcriptase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1996/002540
Other languages
English (en)
Other versions
WO1996041634A2 (fr
Inventor
Colla Paolo La
Maria Elena Marongiu
Giovanna Piras
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SARDINIAN ANTIVIRAL RESEARCH CONSORTIUM - SARC SC
COLLA PAOLO
SARDINIAN ANTIVIRAL RESEARCH C
Original Assignee
SARDINIAN ANTIVIRAL RESEARCH CONSORTIUM - SARC SC
COLLA PAOLO
SARDINIAN ANTIVIRAL RESEARCH C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SARDINIAN ANTIVIRAL RESEARCH CONSORTIUM - SARC SC, COLLA PAOLO, SARDINIAN ANTIVIRAL RESEARCH C filed Critical SARDINIAN ANTIVIRAL RESEARCH CONSORTIUM - SARC SC
Priority to AU63552/96A priority Critical patent/AU6355296A/en
Publication of WO1996041634A2 publication Critical patent/WO1996041634A2/fr
Publication of WO1996041634A3 publication Critical patent/WO1996041634A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne l'utilisation, pour le traitement d'infections à VIH, d'un inhibiteur de transcriptase inverse no n-nucléosidique, notamment des dérivés de 6-benzyl-4-oxopyrimidine de formule générale (I), dans laquelle X est choisi dans le groupe constitué de O, S; R est choisi dans le groupe comprenant alkyle de C1 à C4, cycloalkyle C5 et C6; R', R' et Z sont identiques ou différents et représentent H, alkyle de C1 à C4, sous réserve que lorsque X vaut 0, R et R' ne peuvent être tous les deux égaux à H, leurs sels pharmaceutiquement acceptables et leurs dérivés solubles, en association avec des inhibiteurs de nucléoside choisis dans le groupe constitué de AZT, d4T et leurs dérivés phosphodiesters ou phosphotriesters. L'invention concerne également des compositions pharmaceutiques destinées au traitement d'infections à VIH comprenant une association de différents composants.
PCT/EP1996/002540 1995-06-13 1996-06-12 Utilisation d'un inhibiteur de transcriptase inverse non-nucleosidique en association avec des inhibiteurs de nucleosides pour le traitement d'infections a vih Ceased WO1996041634A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU63552/96A AU6355296A (en) 1995-06-13 1996-06-12 Use of a non-nucleoside reverse transcriptase inhibitor in a ssociation with nucleoside inhibitors for the treatment of h iv infection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITCA95A000009 1995-06-13
IT95CA000009A IT1281502B1 (it) 1995-06-13 1995-06-13 Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della

Publications (2)

Publication Number Publication Date
WO1996041634A2 WO1996041634A2 (fr) 1996-12-27
WO1996041634A3 true WO1996041634A3 (fr) 1997-01-23

Family

ID=11347060

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/002540 Ceased WO1996041634A2 (fr) 1995-06-13 1996-06-12 Utilisation d'un inhibiteur de transcriptase inverse non-nucleosidique en association avec des inhibiteurs de nucleosides pour le traitement d'infections a vih

Country Status (3)

Country Link
AU (1) AU6355296A (fr)
IT (1) IT1281502B1 (fr)
WO (1) WO1996041634A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72207C2 (uk) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
WO2001007027A2 (fr) * 1999-07-22 2001-02-01 Vertex Pharmaceuticals Incorporated Inhibiteurs d'helicase virale
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JP2013500260A (ja) 2009-07-24 2013-01-07 ヴァンダービルト ユニバーシティー アイソフォーム選択的ホスホリパーゼｄ阻害剤
WO2013049773A1 (fr) 2011-09-30 2013-04-04 Vanderbilt University Thérapies antivirales avec des inhibiteurs de phospholipase d
WO2014093553A1 (fr) * 2012-12-11 2014-06-19 Vanderbilt University Méthodes et compositions pour le traitement d'une infection par le vih

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TRAMONTANO E ET AL: "Characterization of the anti-HIV-1 activity of 3,4-dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs), new non-nucleoside reverse transcriptase inhibitors", MICROBIOLOGICA (PAVIA), 17 (4). 1994. 269-279., XP000609825 *

Also Published As

Publication number Publication date
ITCA950009A0 (it) 1995-06-13
AU6355296A (en) 1997-01-09
IT1281502B1 (it) 1998-02-18
ITCA950009A1 (it) 1996-12-13
WO1996041634A2 (fr) 1996-12-27

Similar Documents

Publication Publication Date Title
EP1564210A4 (fr) Composes 4-oxoquinoliniques et leur utilisation comme inhibiteur de la vih-integrase
CA2434906A1 (fr) Utilisation d'un agoniste du recepteur a3 d'adenosine pour l'inhibition de replication virale
EP0707481A4 (fr)
YU13695A (sh) Upotreba 2-fenil-3-aroilbenzotiofena i njihove farmaceutske formulacije
NO953844L (no) 1-amidinofenyl-pyrrolidoner piperidinoner azetinoner som plateaggregeringshemmere
ATE163418T1 (de) Risperidon pamoate
ATE250623T1 (de) 4'-c-ethynyl-purin-nukleoside
YU172991A (sh) Sinergizam inhibitora hiv reverzne transkriptaze
NZ229453A (en) A pharmaceutical composition containing purine derivatives with nucleosides such as azt, as antiviral agents
GR3017128T3 (en) Treatment of hiv infections and compounds useful therein.
ES2108717T3 (es) Derivados de la tetrahidropirrolo(1,2-a)pirazina-4-espiro-3'-pirrolidina, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
HUP0202191A2 (hu) A koagulációs kaszkád szelektív gátlására alkalmas helyettesített policiklusos aril- és heteroaril-pirazinonok, valamint az ezeket tartalmazó gyógyszerkészítmények
WO1996030370A3 (fr) Derives de thiazole et de thiadiazole, leur preparation et compositions pharmaceutiques utiles pour le traitement de la thrombocytopenie
CA2364251A1 (fr) Inhibition synergique de replication virale par des hydrocarbures et analogues nucleosidiques a chaine longue
WO1996041634A3 (fr) Utilisation d'un inhibiteur de transcriptase inverse non-nucleosidique en association avec des inhibiteurs de nucleosides pour le traitement d'infections a vih
AU2001278708A1 (en) Adenosine derivatives and use thereof
IE893991L (en) 2',3'-dideoxypurine nucleoside/purine nucleoside¹phosphorylase inhibitor combination therapy and composition
WO1999019304A3 (fr) Composes de pyrimidine thioalkyl alpha substitues
YU6396A (sh) Kombinacija inhibitora hiv proteaze sa drugim jedinjenjima za terapiju hiv infekcija
EP1065200A4 (fr) Derives d'aminoisoquinoleine
NO983444D0 (no) Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer
CA2213099A1 (fr) Complexes de s-(+)-adenosyl-methionine et de 3'-azido-2',3'-didesoxy-nucleoside, puissants inhibiteurs de la replication du vih
WO2003016266A1 (fr) Composes $g(b)-cetoamides et leur utilisation medicinale
EP1411956B8 (fr) Utilisation de polysaccharides sursulfates comme inhibiteurs du hiv
WO1990005523A3 (fr) Esters de phenanthrolinedicarboxylate, derives de 4-aminoquinoline et isoquinoline en tant qu'inhibiteurs de la transcriptase d'inversion de hiv

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU AZ BB BG BR BY CA CN CZ EE GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AU AZ BB BG BR BY CA CN CZ EE GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA